Product
dacarbazine
Aliases
Dacarbazine, DTIC
Name
Dacarbazine
FDA Approved
Yes
4 clinical trials
3 organizations
1 drug
2 indications
1 document
Indication
Hodgkin lymphomaIndication
Peripheral T Cell LymphomaDrug
TrabectedinClinical trial
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2017-04-20
Clinical trial
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma SubjectsStatus: Active (not recruiting), Estimated PCD: 2022-11-07
Clinical trial
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)Status: Active (not recruiting), Estimated PCD: 2027-02-13
Clinical trial
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard ChemotherapyStatus: Completed, Estimated PCD: 2023-04-07
Document
DailyMed Label: Dacarbazine
Organization
Fresenius Kabi USA, LLC
Organization
Hikma Pharmaceuticals USA Inc.Organization
Meitheal Pharmaceuticals Inc.